Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658578 | 1.00 | MAPT (0.67) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL2791934 | 1.00 | MAPT (0.67) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL2792238 | 0.92 | MAPT (0.68) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL852804 | 0.92 | MAPT (0.74) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL753207 | 0.88 | MAPT (0.65) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL29739592 | 0.83 | MAPT (0.84) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL2791422 | 0.81 | MAPT (0.46) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL2790851 | 0.81 | MAPT (0.46) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL2792160 | 0.81 | MAPT (0.46) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL24267753 | 0.80 | MAPT (0.66) | MAPTL3MBTL1POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511375-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119053599-A | Bicyclic compounds | 安力高医药股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023205653-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-2736900-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130029962-A1 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2013013815-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20130029962-A1 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2013013815-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20130029962-A1 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20080221107-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221107-A1 | Therapeutic Agents | HTT, ACHE, GRIN2A | MAPT 22/4885L3MBTL1 4036/4885POLB 1714/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | MAPT 1168/4885L3MBTL1 4572/4885POLB 3123/4885 |
| US-20130029962-A1 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV3 | MAPT 1363/4885L3MBTL1 4711/4885POLB 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.